Abundant Health Physical Medicine’s unique RENEW Protocols are tailored to help patients reverse neuropathy, repair damaged ...

This newly issued patent will strengthen Ocean Biomedical’s intellectual property portfolio and provides protection in one of the world’s largest pharmaceutical markets. The granted claims cover the ...

“The NDASA conference brings together key voices in workplace drug testing,” said Daniel Brown, Head of Clinical Affairs at Intelligent Bio Solutions. “We’re proud to support its mission and ...

Bill has been an exceptional leader in successfully guiding the company from early research into clinical development and preparing David to assume the role of CEO,” said Leon Chen, Ph.D., MBA, a ...

New robotic technology has arrived at Norton Brownsboro Hospital. Justin M. Givens, M.D., orthopedic surgeon with Norton Orthopedic Institute, is among the first five surgeons in the country — and the ...

Recent sales wins include: A prominent Midwest academic medical center has integrated Daxor’s BVA technology to enhance outpatient cardiovascular care, marking a significant advancement in regional ...

Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it ...

Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for ...

To access Vivos’ investor conference call, please dial (800) 717-1738, or for international callers, (646) 307-1865. A replay will be available shortly after the call and can be accessed by dialing ...

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OA ...

Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after administration of GT-02287, suggest that GT-02287 may have the potential to slow ...

Research and development expenses decreased by $21.7 million to $15.1 million for year ended December 31, 2024, as compared to $36.8 million for the comparable period in 2023. Changes to the ...